Anlon Healthcare Executes Share Swaps to Acquire Stakes in Apiqo Organics and Bizotic Lifescience
Anlon Healthcare Limited has announced that it has executed two significant Share Swap Agreements aimed at acquiring substantial stakes in key companies within the pharmaceutical sector: Apiqo Organics Private Limited (AOPL) and Bizotic Lifescience Private Limited (BLPL). The transactions, completed on August 8, 2026, involve Anlon Healthcare exchanging its equity shares for consideration to acquire a stake in both target entities.The acquisitions are strategically designed to strengthen the supply chain of critical materials for Anlon Healthcare and enhance long-term shareholder value across the board. Both transactions fall under the category of a Related Party Transaction due to shared interest among promoters and some directors in both the acquiring entity and the targets.
Strategic Acquisitions Overview
Anlon Healthcare is set to acquire up to 32.52% shareholding in AOPL through the first swap agreement. The transaction involves issuing equity shares of Anlon in exchange for the target company's existing stake, with no cash consideration expected.The acquisition of Apiqo Organics Private Limited (AOPL), a firm engaged in manufacturing pharmaceutical intermediate and industrial chemicals, is structured as follows:
| Financial Detail | Details |
|---|---|
| Target Entity | Apiqo Organics Private Limited (AOPL) |
| Industry | Pharmaceuticals |
| Acquisition Target | Up to 32.52% shareholding |
| Cost of Acquisition | Rs. 1,165,179,600/- |
| Shares Acquired | Up to 45,16,200 equity shares at Rs. 258/- each |
| Timeline | Expected within 90 days of signing the AOPL SSA |
In addition, Anlon Healthcare is set to acquire up to 43.33% shareholding in Bizotic Lifescience Private Limited (BLPL). This acquisition aims to strengthen operational efficiency and long-term competitiveness by acquiring a stake in BLPL, which focuses on manufacturing Active Pharmaceutical Ingredients (API) and related services.
| Financial Detail | Details |
|---|---|
| Target Entity | Bizotic Lifescience Private Limited (BLPL) |
| Industry | Pharmaceuticals |
| Acquisition Target | Up to 43.33% shareholding |
| Cost of Acquisition | Rs. 367,840,000/- |
| Shares Acquired | Up to 22,99,000 equity shares at Rs. 160/- each |
| Timeline | Expected within 90 days of signing the BLPL SSA |
Equity Issuance Details
The transactions involve the issuance and allotment of up to 8,58,83,617 Equity Shares of Anlon Healthcare for consideration other than cash. The issue price is set at Rs. 17.85/- per equity share.The issuance details are as follows:
| Detail | Specification |
|---|---|
| Type of Issuance | Preferential Allotment for consideration other than cash (share swap) |
| Shares to be Issued | Up to 8,58,83,617 Equity Shares |
| Face Value | Rs.02/- per share |
Shareholding Updates
The company has provided pre and post-allotment details of its shareholding structure for the involved shareholders, assuming full acceptance of the share swap proposal by all parties.Details regarding the change in shareholding in AOPL (Target 1) upon completion of the preferential allotment are presented below:
| Shareholder Name | Pre-Preferential Holding (No. of Shares) | Post-Allotment Holding (No. of Shares) |
|---|---|---|
| Punitkumar Rameshbhai Rasadia | 18,59,20,000 | 20,43,39,402 |
| Meet Atulkumar Vachhani | 9,40,80,000 | 10,34,31,099 |
For BLPL (Target 2), the shareholding updates are as follows:
| Shareholder Name | Pre-Preferential Holding (No. of Shares) | Post-Allotment Holding (No. of Shares) |
|---|---|---|
| Punitkumar Rameshbhai Rasadia | 18,59,20,000 | 20,43,39,402 |
| Meet Atulkumar Vachhani | 9,40,80,000 | 10,34,31,099 |
AHCL Stock Price Movement
On Friday, Anlon Healthcare Limited shares edged higher to close at ₹14.55, gaining 2.81% in the session. The stock settled amidst robust trading activity, with a volume recorded of 3.20 million shares.Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.
Any views, opinions, or statements expressed, where applicable, are those of the respective analysts or experts and do not reflect the views of this website. The website has no association with such viewpoints and does not assume any responsibility for them.
Last edited by a moderator: